BioNTech’s second act: can it transform the fight against cancer?
16 min
Vaccine protection won't last as long as initially thought. The pharmaceutical AstraZeneca has gone through several rough patches in 2021, thanks to its COVID-19 vaccine developed in collaboration with Oxford University. But, the Swedish company may have finally found a break in the form of monoclonal antibody treatment, the first long-acting preventative method against the virus. Could this be a more effective way to battle COVID than vaccines? Therese Raphael contemplates.